Patients With R/R CLL Have Promising Efficacy Outcomes With Zanubrutinib
Cancer Network,
Moreover, 6.6% of patients (n = 6) achieved a complete response (CR) as their best response to treatment, 69.2% (n = 63…
Zanubrutinib Demonstrates Impressive Responses in Relapsed/Refractory CLL
OncLive,
At 34 months of follow-up (range, 0.8-41.4), the BTK inhibitor elicited an objective response rate (ORR) of 87.9% per…
Pair of Studies Highlight Zanubrutinib Tolerability, Efficacy, Utility
AJMC,
The first study, 1 which took place in China, encompassed 91 patients with a median age of 61 (range, 35-87) years who had…
Zanubrutinib Shows High Response Rates in Single-Arm Phase 2 Study
AJMC,
The bruton tyrosine kinase inhibitor zanubrutinib was shown to generate high response rates in a new study of patients with…